We are live on ! Find out more

CPRX

Catalyst Pharmaceutical

CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

130 hedge funds and large institutions have $236M invested in Catalyst Pharmaceutical in 2019 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 47 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New

Increased

Maintained

Reduced

Closed

76% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 17

38% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 34

11% more funds holding

Funds holding: 117 → 130 (+13)

1.15% more ownership

Funds ownership: 59.82% → 60.98% (+1.2%)

28% less capital invested

Capital invested by funds: $327M → $236M (-$91.5M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

79% less call options, than puts

Call options by funds: $70K | Put options by funds: $340K

Holders

130

Holders Change

+13

Holders Change %

+11.11%

% of All Funds

2.56%

Holding in Top 10

Holding in Top 10 Change

-1

Holding in Top 10 Change %

-50%

% of All Funds

0.02%

New

Increased

Reduced

Closed

Calls

$70K

Puts

$340K

Net Calls

-$270K

Net Calls Change

+$438K

Top Buyers

1	AC Armistice Capital New York	+$23.8M
2	State Street Boston, Massachusetts	+$17.7M
3	N Nuveen Charlotte, North Carolina	+$8.18M
4	Marshall Wace London, United Kingdom	+$7.33M
5	Citadel Advisors Miami, Florida	+$5.28M

Top Sellers

1	CCM Consonance Capital Management New York	-$94.9M
2	EA Emerald Advisers Leola, Pennsylvania	-$6.24M
3	EMFAT Emerald Mutual Fund Advisers Trust Leola, Pennsylvania	-$5.75M
4	AI Atom Investors Austin, Texas	-$5.38M
5	BC Broadfin Capital New York	-$4.67M

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	26 Wells Fargo San Francisco, California	$1.87M	+$241K	+51,559	+12%
27	27 Deutsche Bank Frankfurt Am Main Ge, Germany	$1.83M	+$2.16M	+461,609	+1,650%
28	28 Two Sigma Advisers New York	$1.71M	+$2.08M	+444,200	+3,446%
29	QI 29 QS Investors New York	$1.7M	+$2.1M	+449,000	+37,986%
30	30 Bank of New York Mellon New York	$1.62M	+$212K	+45,432	+12%
31	31 Dimensional Fund Advisors Austin, Texas	$1.58M	+$79.5K	+16,990	+4%
32	PP 32 PDT Partners New York	$1.48M	+$987K	+210,977	+114%
33	33 Rafferty Asset Management New York	$1.36M	+$902K	+192,878	+114%
34	34 Schroder Investment Management Group London, United Kingdom	$1.33M	+$1.65M	+353,757	New
35	CCM 35 Cadence Capital Management Boston, Massachusetts	$1.27M	-$156K	-33,354	-9%
36	BGIM 36 Brandywine Global Investment Management Philadelphia, Pennsylvania	$1.26M	+$251K	+53,735	+19%
37	37 Voloridge Investment Management Jupiter, Florida	$1.07M	+$1.25M	+267,101	+1,527%
38	TCM 38 Tanaka Capital Management New York	$1.06M	-$4.26K	-910	-0.3%
39	OAM 39 Oxford Asset Management Oxford, United Kingdom	$973K	+$507K	+108,409	+72%
40	PAM 40 Panagora Asset Management Boston, Massachusetts	$963K	-$203K	-43,314	-14%
41	41 Russell Investments Group London, United Kingdom	$896K	+$1.12M	+239,656	New
42	RJFSA 42 Raymond James Financial Services Advisors St. Petersburg, Florida	$888K	–	–	–
43	43 Jacobs Levy Equity Management Florham Park, New Jersey	$842K	+$32.6K	+6,965	+3%
44	AA 44 ALPS Advisors Denver, Colorado	$784K	+$978K	+209,190	New
45	45 California Public Employees Retirement System Sacramento, California	$765K	+$317K	+67,876	+50%
46	46 Citigroup New York	$754K	+$522K	+111,656	+125%
47	BPM 47 Bowling Portfolio Management Cincinnati, Ohio	$744K	+$927K	+198,334	New
48	48 Susquehanna International Group Bala Cynwyd, Pennsylvania	$732K	-$600K	-128,271	-40%
49	GCP 49 GSA Capital Partners London, United Kingdom	$703K	+$715K	+152,858	+441%
50	CIA 50 Capital Impact Advisors Boston, Massachusetts	$675K	–	–	–

CPRX Hedge Fund Activity: Q4 2019 in Review

130 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2019, worth a combined $236M — down 28% from $327M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new CPRX positions and 17 closed out — a net gain of 13 holders — while 47 added to existing stakes and 34 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $23.8M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $94.9M sold.

130 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2019, up from 117 in Q3 2019.
Funds reported $236M of Catalyst Pharmaceutical stock for Q4 2019, down 28% quarter-over-quarter.
30 funds opened new Catalyst Pharmaceutical positions in Q4 2019 and 17 closed out, a net change of +13 holders.
The largest Catalyst Pharmaceutical buyer in Q4 2019 was Armistice Capital, an estimated $23.8M added.
The largest Catalyst Pharmaceutical seller in Q4 2019 was Consonance Capital Management, an estimated $94.9M sold.

Based on aggregated 13F filings for Q4 2019.

Catalyst Pharmaceutical CPRX